Beneficial effects of Brassica juncea on cognitive functions in rats

Figures & data

Figure 1. HPLC chromatogram of: (a) polyphenols standard and (b) a hydrolyzed sample of the methanol Brassica juncea leaf extract.

Figure 2. Effect of BJ in transfer latency test on elevated plus maze in scopolamine amnesia model and alloxan induced diabetic rats. *p < 0.05 versus nondiabetic control; ^¥p < 0.05 versus scopolamine control; ^$p < 0.05 versus diabetic control; ^ap < 0.05 versus the values of the same group on day 2.

Figure 3. Effect of BJ extract on passive avoidance retention deficits in scopolamine induced amnesia model and alloxan induced diabetic rats. *p < 0.05 versus nondiabetic control; ^¥p < 0.05 versus scopolamine control; ^$p < 0.05 versus diabetic control; ^ap < 0.05 versus the values of the same group on day 2.

Figure 4. Effect of BJ extract on active avoidance test namely: (a) shocked trials (b) total trials and (c) total time in scopolamine-induced amnesia model and in alloxan-induced diabetic rats. *p < 0.05 versus nondiabetic control; ^¥p < 0.05 versus scopolamine control; ^$p < 0.05 versus diabetic control; ^ap < 0.05 versus the values of the same group on day 2.

Table 1. Effect of BJ on AChE enzymes, SOD and CAT activity in scopolamine-induced nondiabetic amnesic and alloxan-induced diabetic rats.

Treatment	Dose (mg/kg)	AChE activity (µmol substrate/min/mg protein)	SOD (U/min/mg protein)	CAT (µmol//min/mg protein)
ND control (0.3% CMC)	–	15.45 ± 0.70	5.26 ± 0.23	46.00 ± 1.99
ND control + Scopolamine	1	24.96 ± 0.89^a	2.00 ± 0.17^a	21.48 ± 0.82^a
ND + Scopolamine + BJ	1 + 100	21.31 ± 0.46^b	3.16 ± 0.30^b	27.15 ± 1.03^b
ND + Scopolamine + BJ	1 + 200	19.71 ± 0.80^b	3.45 ± 0.16^b	30.61 ± 1.31^b
ND + Scopolamine + BJ	1 + 400	18.38 ± 0.81^b	4.50 ± 0.18^b	35.25 ± 1.44^b
Diabetic control (0.3% CMC)	–	25.18 ± 1.13^a	2.26 ± 0.17^a	19.50 ± 1.18^a
Diabetic + BJ	100	21.73 ± 1.04^c	2.86 ± 0.11^c	24.56 ± 1.20^c
Diabetic + BJ	200	19.29 ± 0.97^c	3.09 ± 0.20^c	26.06 ± 1.25^c
Diabetic + BJ	400	18.28 ± 1.08^c	4.47 ± 0.22^c	31.52 ± 1.20^c

^ap < 0.05 versus nondiabetic control.

^bp < 0.05 versus scopolamine control.

^cp < 0.05 versus diabetic control.